Dermal lymphatic invasion and inflammatory breast cancer are independent predictors of outcome after postmastectomy radiation

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 1, 2009, Pages 30-33

  Abramowitz, Matthew C ^a   Li, Tianyu ^a   Morrow, Monica ^a   Sigurdson, Elin R ^a   Anderson, Penny ^a   Nicolaou, Nicos ^a   Freedman, Gary ^a,b  

^a FOX CHASE CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

Dermal lymphatic invasion; Inflammatory breast cancer; Locally advanced breast cancer; Postmastectomy radiation

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREDICTOR VARIABLE; BREAST TUMOR; INFLAMMATION; LYMPH NODE; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SKIN; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SKIN; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 60549108438     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31817b6073     Document Type: Article

References (23)

1. Lee BJ, Tannenbaum NE. Inflammatory carcinoma of the breast. Surg Gynecol Obst. 1924;39:580-595.
2. Bryant T. Diseases of the breast. Wood's Med Surg Monogr. 1889;4:35-322.
3. Taylor GW, Meltzer A. "Inflammatory carcinoma" of the breast. Am. J. Cancer. 1938;33:33-49.
4. Bonnier P, Charpin C, Lejeune C, et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer. 1995;62:382-385.
5. Amparo RS, Angel CD, Ana LH, et al. Inflammatory breast carcinoma: pathological or clinical entity? Breast Cancer Res Treat. 2000;64:269-273.
6. Frederick L. Greene MD, eds. AJCC Cancer Staging Handbook. 6th ed. New York: Springer-Verlag; 2002.
7. Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer. 1994;74:466-476.
8. Lucas FV, Perez-Mesa C. Inflammatory carcinoma of the breast. Cancer. 1978;41:1595-1605.
9. Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index. J Clin Oncol. 1998;16:3731-3735.
10. Chang S, Parker SL, Pham T, et al. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer. 1998;82:2366-2372.
11. Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966-975.
12. Levine PH, Steinhorn SC, Ries LG, et al. Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst. 1985;74:291-297.
13. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40:321-329.
14. Veyret C, Levy C, Chollet P, et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer. 2006;107:2535-2544.
15. Chevallier B, Asselain B, Kunlin A, et al. Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. Cancer. 1987;60:897-902.
16. Burton GV, Cox EB, Leight GS, Jr., et al. Inflammatory breast carcinoma. Effective multimodal approach. Arch Surg. 1987;122:1329-1332.
17. Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004;22:4067-4074.
18. Fields JN, Perez CA, Kuske RR, et al. Inflammatory carcinoma of the breast: treatment results on 107 patients. Int J Radiat Oncol Biol Phys. 1989;17:249-255.
19. Bozzetti F, Saccozzi R, De Lena M, et al. Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol. 1981;18:355-361.
20. Koh EH, Buzdar AU, Ames FC, et al. Inflammatory carcinoma of the breast: results of a combined-modality approach-MD Anderson Cancer Center experience. Cancer Chemother Pharmacol. 1990;27:94-100.
21. Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol. 2005;23:1941-1950.
22. Lamb CC, Eberlein TJ, Parker LM, et al. Results of radical radiotherapy for inflammatory breast cancer. Am J Surg. 1991;162:236-242.
23. Fein DA, Mendenhall NP, Marsh RD, et al. Results of multimodality therapy for inflammatory breast cancer: an analysis of clinical and treatment factors affecting outcome. Am Surg. 1994;60:220-225.